Drugs / Imrecoxib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02426060 | Jan → Mar 2015 | osteoarthritis, knee | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02456688 | Jan → Jun 2015 | osteoarthritis, knee | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01985165 | May → Nov 2013 | osteoarthritis, knee | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03932006 Comparator | Jun 2016 → May 2019 | ankylosing spondylitis | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imrecoxib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01985165 ↗ |
| Known as | BAP-909 | ChEMBL registry synonym — accepted as the source's own label CHEMBL504535 ↗ |
| Action | Inhibit | “primarily inhibits COX-2 and not COX-1 at therapeutic doses” NCT02426060 ↗ |
| Modality | Small molecule | — CHEMBL504535 ↗ |
| Route | Oral | “0.1g,BID,po” NCT01985165 ↗ |